Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07321912 · ClinicalTrials.gov registry record · Phase 2
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
A Phase 2 study, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT07321912 is a Phase 2 study that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 406 participants.
The verdict
NCT07321912, a Phase 2 study, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Vincristine
- DRUG Topotecan
- DRUG Eflornithine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2036-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07321912
The ClinicalTrials.gov registry entry for NCT07321912 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07321912 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07321912 about?
NCT07321912 is a clinical study titled "Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma". Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenanc...
What is the current status of trial NCT07321912?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2026-06-05. Estimated completion is 2036-06-01.
What interventions are being tested in trial NCT07321912?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Vincristine (DRUG), Topotecan (DRUG), Eflornithine (DRUG).
Who is sponsoring clinical trial NCT07321912?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.